Stock Fundamentals

Company Information

Company Name
MacroGenics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US5560991094
CIK: 0001125345
CUSIP: 556099109
Currency: USD
Full Time Employees: 293
Phone: 301 251 5172
Fiscal Year End: December
IPO Date: Oct 10, 2013
Description:

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Address:

9704 Medical Center Drive, Rockville, MD, United States, 20850

Directors & Officers

Name Title Year Born
Mr. Eric Blasius Risser CEO, President & Director 1973
Mr. James Karrels Senior VP & CFO 1967
Dr. Ezio Bonvini M.D. Senior VP of Research & Chief Scientific Officer 1954
Dr. Thomas M. Spitznagel Ph.D. Senior Vice President of Technical Operations 1967
Mr. Jeffrey Stuart Peters J.D. Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer 1971
Mr. Steve Harig Senior Vice President of Human Resources NA
Mr. Harish Krishnaswamy Senior Vice President of Business Development & Portfolio Planning NA
Dr. Frank George Perabo FEBU, M.D., Ph.D. Vice President & Interim Head of Clinical Development 1964
Ms. Beth Smith VP, Controller & Treasurer 1968

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Aug 20, 2025 William K Heiden N/A Purchase 49.50K $1.49 $73.76K
Aug 19, 2025 William K Heiden N/A Purchase 50.50K $1.52 $76.76K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Armistice Capital, LLC 6.01M Mar 31, 2026 9.46% $0.31 -4.93%
Vanguard Group Inc 4.23M Dec 31, 2025 6.65% $0.00 0.06%
Renaissance Technologies Corp 2.96M Mar 31, 2026 4.66% $0.01 1.89%
Millennium Management LLC 2.79M Mar 31, 2026 4.40% $0.00 41.52%
Vanguard Capital Management, LLC 2.65M Mar 31, 2026 4.18% $0.00 0.00%
Acadian Asset Management LLC 2.54M Mar 31, 2026 4.00% $0.01 199,116.91%
Two Sigma Investments LLC 2.53M Mar 31, 2026 3.98% $0.01 152.92%
Bank of America Corp 2.40M Mar 31, 2026 3.78% $0.00 30.70%
Marshall Wace Asset Management Ltd 2.03M Mar 31, 2026 3.19% $0.01 57.68%
RA Capital Management, LLC 1.86M Mar 31, 2026 2.93% $0.06 0.00%
Wasatch Advisors LP 1.56M Mar 31, 2026 2.45% $0.03 -12.69%
Vanguard Portfolio Management, LLC 1.21M Mar 31, 2026 1.90% $0.00 0.00%
Two Sigma Advisers, LLC 1.20M Dec 31, 2025 1.88% $0.00 59.63%
BlackRock Inc 1.16M Mar 31, 2026 1.83% $0.00 0.91%
D. E. Shaw & Co LP 1.06M Mar 31, 2026 1.67% $0.00 39.88%
Connor Clark & Lunn Inv Mgmt Ltd 867.25K Mar 31, 2026 1.36% $0.01 5.91%
Citadel Advisors Llc 782.62K Mar 31, 2026 1.23% $0.00 -24.40%
Geode Capital Management, LLC 697.32K Mar 31, 2026 1.10% $0.00 6.41%
Jane Street Group LLC 608.51K Mar 31, 2026 0.96% $0.00 -51.51%
Diadema Partners LP 600.00K Mar 31, 2026 0.94% $0.30 0.00%

Shares Statistics

Shares Outstanding: 63.56M
Shares Float: 52.44M
% Insiders: 342.60%
% Institutions: 7,107.90%
Short % Float: 10.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 BB Biotech AG Ord 9.92M 15.61% ▲ 0.00% Sep 30, 2025
2 Vanguard Total Stock Mkt Idx Inv 1.93M 3.03% ▲ 0.00% Apr 30, 2026
3 Wasatch Ultra Growth 1.43M 2.26% ▼ 13.72% Mar 31, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 651.75K 1.03% ▲ 0.00% Apr 30, 2026
5 Vanguard Strategic Small-Cap Equity Inv 438.60K 0.69% ▲ 0.00% Mar 31, 2026
6 Vanguard VIF Small Co Gr 437.61K 0.69% ▲ 0.00% Mar 31, 2026
7 Nomura Healthcare Fund Class I 420.00K 0.66% ▲ 0.00% Apr 30, 2026
8 PPF Helix Biotechnology I USD 384.00K 0.60% ▲ 6,235.59% Sep 30, 2025
9 PSM Value Strategy UI 360.00K 0.57% ▲ 20.00% Jan 31, 2026
10 Fidelity Extended Market Index 320.07K 0.50% ▼ 0.36% Apr 30, 2026

Valuation Metrics

Enterprise Value: $157.51M
Trailing P/E: 0.00
Forward P/E: 60.98

Financial Highlights

Market Cap: $275.23M
EBITDA: $-56.57M
PEG Ratio: $0.01
Book Value: $0.33
Earnings/Share: $-1.11
Profit Margin: -44.79%
Operating Margin: -160.96%
ROA (TTM): -17.98%
ROE (TTM): -140.27%
Revenue (TTM): $157.08M
Revenue/Share (TTM): $2.48
Earnings Growth (YOY): -70.40%
Revenue Growth (YOY): 57.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.10x 0.09x 0.78x -8.56x -0.09x
2024-12-31 3.92x 0.04x 0.56x -99.17x -0.08x
2023-12-31 4.48x 0.02x 0.49x -117.65x 1.87x
2022-12-31 4.57x 0.03x 0.51x -461.67x -0.04x
2021-12-31 3.75x 0.02x 0.29x -298.23x -0.02x
2020-12-31 6.17x 0.01x 0.22x N/A -0.03x
2019-12-31 5.31x 0.01x 0.26x N/A -0.02x
2018-12-31 4.49x 0.14x 0.27x N/A -0.21x
2017-12-31 6.48x 0.00x 0.20x N/A -0.02x
2016-12-31 10.40x 0.01x 0.14x N/A -0.03x
2015-12-31 14.70x 0.01x 0.13x N/A -0.12x
2014-12-31 6.08x 0.01x 0.30x N/A -0.04x
2013-12-31 4.14x 18.23x 0.37x N/A 922.67x
2012-12-31 1.68x -0.15x 1.15x N/A 0.13x
2011-12-31 1.32x -0.06x 1.28x N/A 0.16x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MGNX.US!